Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: A comprehensive genetic profiling and survival analysis

Journal of Human Genetics

Volumn 59, Issue 3, 2014, Pages 124-128

  Sio, Terence T ^a   Mansfield, Aaron S ^a   Grotz, Travis E ^a   Graham, Rondell P ^a   Molina, Julian R ^a   Que, Florencia G ^a   Miller, Robert C ^a  

^a MAYO CLINIC   (United States)

Author keywords

colorectal cancer; JUN; MCL1; next generation sequencing; pseudomyxoma peritonei

Indexed keywords

CETUXIMAB; CHROMIUM PHOSPHATE P 32; FLUOROURACIL; FOLINIC ACID; FORMALDEHYDE; IRINOTECAN; K RAS PROTEIN; MYC PROTEIN; OXALIPLATIN; PARAFFIN; PROTEIN C JUN; PROTEIN MCL 1; GNAS PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MCL1 PROTEIN, HUMAN; MYELOID LEUKEMIA FACTOR 1; ONCOPROTEIN; RAS PROTEIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERITONEUM PSEUDOMYXOMA; PROTEIN EXPRESSION; SURVIVAL; TUMOR GENE; VERY ELDERLY; DEMOGRAPHY; GENE REARRANGEMENT; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; DEMOGRAPHY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-JUN; PSEUDOMYXOMA PERITONEI; RAS PROTEINS; SURVIVAL ANALYSIS;

EID: 84896994322     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2013.132     Document Type: Article

References (37)

1. Smeenk, R. M., van Velthuysen, M. L., Verwaal, V. J. & Zoetmulder, F. A. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur. J. Surg. Oncol. 34, 196-201 (2008).
2. Hinson, F. L. & Ambrose, N. S. Pseudomyxoma peritonei. Br. J. Surg. 85, 1332-1339 (1998). (Pubitemid 28468332)
3. Chua, T. C., Moran, B. J., Sugarbaker, P. H., Levine, E. A., Glehen, O., Gilly, F. N. et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J. Clin. Oncol. 30, 2449-2456 (2012).
4. Austin, F., Mavanur, A., Sathaiah, M., Steel, J., Lenzner, D., Ramalingam, L. et al. Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann. Surg. Oncol. 19, 1386-1393 (2012).
5. Schomas, D. A., Miller, R. C., Donohue, J. H., Gill, S., Thurmes, P. J., Haddock, M. G. et al. Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: long-term follow-up of the Mayo Clinic experience. Ann. Surg. 249, 588-595 (2009).
6. Han, S. W., Kim, H. P., Shin, J. Y., Jeong, E. G., Lee, W. C., Lee, K. H. et al. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PLoS One 8, e64271 (2013).
7. Chen, J., Ye, Y., Sun, H. & Shi, G. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-Analysis. Cancer Chemother. Pharmacol. 71, 265-272 (2013).
8. Al-Sohaily, S., Biankin, A., Leong, R., Kohonen-Corish, M. & Warusavitarne, J. Molecular pathways in colorectal cancer. J. Gastroenterol. Hepatol. 27, 1423-1431 (2012).
9. Ronnett, B. M., Zahn, C. M., Kurman, R. J., Kass, M. E., Sugarbaker, P. H. & Shmookler, B. M. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to pseudomyxoma peritonei. Am. J. Surg. Pathol. 19, 1390-1408 (1995).
10. Yelensky, R., Wang, K., Dogan, S., Borsu, L., Frampton, G., Lipson, D. et al. Nextgeneration sequencing of FFPE solid tumor specimens for clinical use. J Clin Oncol (Suppl), Abstract 10524 (2012).
11. Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18, 382-384 (2012).
12. Wilson, E. B. & Hilferty, M. M. The distribution of chi-square. Proc. Natl Acad. Sci. USA 17, 684-688 (1931).
13. Kaplan, E. L. & Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481 (1958).
14. Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P. & Craig, R. W. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl Acad. Sci. U S A 90, 3516-3520 (1993). (Pubitemid 23111397)
15. Craig, R. W., Jabs, E. W., Zhou, P., Kozopas, K. M., Hawkins, A. L., Rochelle, J. M. et al. Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: MCL1 maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease. Genomics 23, 457-463 (1994). (Pubitemid 24308268)
16. Moshynska, O., Sankaran, K., Pahwa, P. & Saxena, A. Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J. Natl Cancer Inst. 96, 673-682 (2004). (Pubitemid 38660230)
17. Schulze-Bergkamen, H., Fleischer, B., Schuchmann, M., Weber, A., Weinmann, A., Krammer, P. H. et al. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer 6, 232 (2006).
18. Ding, Q., He, X., Xia, W., Hsu, J. M., Chen, C. T., Li, L. Y. et al. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res. 67, 4564-4571 (2007). (Pubitemid 46910160)
19. Song, L., Coppola, D., Livingston, S., Cress, D. & Haura, E. B. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol. Ther. 4, 267-276 (2005). (Pubitemid 41351285)
20. Allen, T. D., Zhu, C. Q., Jones, K. D., Yanagawa, N., Tsao, M. S. & Bishop, J. M. Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer. Cancer Res. 71, 2212-2221 (2011).
21. Hogarty, M. D. Mcl1 becomes ubiquitin-ous: new opportunities to antagonize a prosurvival protein. Cell Res. 20, 391-393 (2010).
22. Graidist, P., Phongdara, A. & Fujise, K. Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracil- induced cytotoxicity. J. Biol. Chem. 279, 40868-40875 (2004). (Pubitemid 39287685)
23. Bohmann, D., Bos, T. J., Admon, A., Nishimura, T., Vogt, P. K. & Tjian, R. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 238, 1386-1392 (1987). (Pubitemid 18015958)
24. Haluska, F. G., Huebner, K., Isobe, M., Nishimura, T., Croce, C. M. & Vogt, P. K. Localization of the human JUN protooncogene to chromosome region 1p31-32. Proc. Natl Acad. Sci. USA 85, 2215-2218 (1988). (Pubitemid 24315860)
25. Hattori, K., Angel, P., Le Beau, M. M. & Karin, M. Structure and chromosomal localization of the functional intronless human JUN protooncogene. Proc. Natl Acad. Sci. USA 85, 9148-9152 (1988). (Pubitemid 19001855)
26. Wang, D. G., Johnston, C. F. & Buchanan, K. D. Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis. Cancer 80, 668-675 (1997). (Pubitemid 27339821)
27. Volm, M., Drings, P. & Wodrich, W. Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas. J. Cancer Res. Clin. Oncol. 119, 507-510 (1993). (Pubitemid 23180039)
28. Shetty, S., Thomas, P., Ramanan, B., Sharma, P., Govindarajan, V. & Loggie, B. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis. J. Surg. Res. 180, 97-103 (2013).
29. Kabbani, W., Houlihan, P. S., Luthra, R., Hamilton, S. R. & Rashid, A. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod. Pathol. 15, 599-605 (2002). (Pubitemid 34666462)
30. Cuatrecasas, M., Matias-Guiu, X. & Prat, J. Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei: a clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations. Am. J. Surg. Pathol. (1996)20, 739-746. (Pubitemid 26147472)
31. Szych, C., Staebler, A., Connolly, D. C., Wu, R., Cho, K. R. & Ronnett, B. M. Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women. Am. J. Pathol. 154, 1849-1855 (1999). (Pubitemid 29262868)
32. Nash, G. M., Gimbel, M., Cohen, A. M., Zeng, Z. S., Ndubuisi, M. I., Nathanson, D. R. et al. KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann. Surg. Oncol. 17, 416-424 (2010).
33. Andreyev, H. J., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J. et al. Kirsten ras mutations in patients with colorectal cancer: the RASCAL II study. Br. J. Cancer 85, 692-696 (2001). (Pubitemid 32929467)
34. Ahnen, D. J., Feigl, P., Quan, G., Fenoglio-Preiser, C., Lovato, L. C., Bunn, P. A. Jr et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 58, 1149-1158 (1998). (Pubitemid 28183202)
35. Landis, C. A., Masters, S. B., Spada, A., Pace, A. M., Bourne, H. R. & Vallar, L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340, 692-696 (1989). (Pubitemid 19214389)
36. Lyons, J., Landis, C. A., Harsh, G., Vallar, L., Grunewald, K., Feichtinger, H. et al. Two G protein oncogenes in human endocrine tumors. Science 249, 655-659 (1990). (Pubitemid 20259082)
37. Nishikawa, G., Sekine, S., Ogawa, R., Matsubara, A., Mori, T., Taniguchi, H. et al. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br. J. Cancer 108, 951-958 (2013).